Reviewed by
Brandon Johnson — Certified Personal Trainer, Nutrition Coach & Peptide Research Consultant
Brandon Johnson is a certified personal trainer, nutrition coach, and peptide research consultant with a background in kinesiology and over 15 years of experience in fitness and wellness. He reviews all PSPeptides educational content for scientific accuracy and practical relevance.
Understanding the proper tesamorelin dosage is essential for researchers working with the only FDA-approved growth hormone releasing hormone (GHRH) peptide in existence. Tesamorelin (brand name Egrifta) was approved by the FDA in 2010 for the reduction of excess visceral abdominal fat in HIV-associated lipodystrophy — making it the most clinically validated GHRH analog available. A pooled analysis of 806 participants across two Phase III randomized controlled trials (Falutz et al.) demonstrated that the standard tesamorelin dosage reduced visceral adipose tissue by approximately 15.4% versus placebo at 26 weeks (p<0.001). The new F8 formulation, EGRIFTA WR, gained FDA approval on March 25, 2025.
PSPeptides carries research-grade tesamorelin from $59.99 at 99%+ HPLC-verified purity with batch-specific COAs from independent laboratories. This guide covers the tesamorelin dosage used in clinical trials, the GHRH mechanism, visceral fat research data, how tesamorelin compares to other GHRH analogs (Sermorelin, CJC-1295), and practical protocol guidance.
How Tesamorelin Works: The GHRH Mechanism
Tesamorelin is a synthetic analog of human growth hormone releasing hormone (GHRH 1-44) with a trans-3-hexenoic acid modification that improves stability and bioavailability. The standard tesamorelin dosage activates the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells through the Gs/cAMP/PKA signaling pathway — stimulating pulsatile growth hormone (GH) release. This is the same receptor pathway that Sermorelin and CJC-1295 target, but tesamorelin is the only GHRH analog with FDA approval and Phase III clinical trial validation.
The GH released in response to the tesamorelin dosage drives IGF-1 elevation, which mediates the compound’s effects on body composition — particularly the reduction of visceral adipose tissue (VAT) that accumulates around internal organs. This visceral fat specificity distinguishes tesamorelin from general weight loss compounds: the tesamorelin dosage targets the metabolically dangerous deep abdominal fat rather than subcutaneous fat. The CJC-1295/Ipamorelin guide covers the GHRH pathway in detail.
Tesamorelin Dosage: The Clinical Protocol
| Parameter | Clinical Trial Protocol | Notes |
|---|---|---|
| Tesamorelin dosage | 2mg subcutaneous daily | FDA-approved dose (Egrifta/Egrifta WR) |
| Timing | Once daily, consistent time | Morning or evening |
| Administration | Subcutaneous injection (abdomen) | Rotate injection sites |
| Trial duration | 26 weeks (Phase III) | Extended studies to 52+ weeks |
| Visceral fat reduction | ~15.4% vs placebo (pooled) | Falutz et al., 806 participants |
| GH increase | Significant vs baseline | Pulsatile, physiological pattern |
| IGF-1 increase | Dose-dependent elevation | Within normal range at 2mg |
The standard tesamorelin dosage of 2mg daily was established through the Phase III program and is the FDA-approved therapeutic dose. The free reconstitution calculator supports tesamorelin dosage preparation at any concentration. The reconstitution guide covers preparation technique.
Tesamorelin Dosage vs Other GHRH Analogs
| Compound | Typical Dose | FDA Status | Clinical Validation | PSPeptides Price |
|---|---|---|---|---|
| Tesamorelin | 2mg daily | FDA-approved (2010) | Phase III, 806 participants | From $59.99 |
| Sermorelin | 200-300mcg daily | Previously approved (withdrawn) | Phase III (historical) | $44.99-$79.99 |
| CJC-1295 No DAC | 100-200mcg 2-3x daily | Not approved | Phase I/II | $35.99 |
| CJC/Ipa Blend | 100/100mcg 2-3x daily | Not approved | Components studied separately | $65.99 |
The tesamorelin dosage advantage over other GHRH analogs: FDA approval provides the most comprehensive safety and efficacy characterization available for any GHRH peptide. The Phase III validation with 806 participants gives researchers the highest-confidence dosing data in the GHRH class. The stacking guide covers GHRH + GHRP combinations. The half-life chart covers GH peptide timing.
Tesamorelin Dosage: Visceral Fat Research in Detail
The clinical significance of the tesamorelin dosage for visceral fat research cannot be overstated. Visceral adipose tissue (VAT) is the metabolically active deep abdominal fat associated with cardiovascular disease risk, insulin resistance, systemic inflammation, and metabolic syndrome. The pooled Phase III data demonstrating 15.4% VAT reduction with the standard tesamorelin dosage represents one of the strongest evidence bases for any peptide compound targeting metabolic body composition.
Published research also documents that the tesamorelin dosage reduces trunk fat, improves lipid profiles (triglycerides, cholesterol ratios), and may improve cardiovascular biomarkers — effects that extend beyond simple fat reduction to broader metabolic improvement. For researchers studying the GH-visceral fat axis, the tesamorelin dosage protocol provides the most clinically validated starting point available.
Buy Tesamorelin at PSPeptides
PSPeptides carries research-grade tesamorelin from $59.99. 99%+ HPLC-verified purity with batch-specific COAs from independent laboratories. Free shipping, same-day processing including Sundays, zero fees on Affirm, Afterpay, Zelle, cards, Apple Pay, Google Pay. bacteriostatic water ($19.99), EasyTouch syringes, and alcohol prep pads in the same checkout. free reconstitution calculator for tesamorelin dosage preparation. 24/7 support via live chat, email ([email protected]), phone/text (551) 284-2670. Discrete plain white mailer packaging with generic billing descriptors. The tesamorelin dosage protocol — and the entire GH secretagogue catalog (Sermorelin, CJC-1295, CJC/Ipa Blend, Ipamorelin) — is available at PSPeptides. PubMed indexes tesamorelin clinical data. Wikipedia covers tesamorelin pharmacology. The weight loss peptide guide covers the metabolic landscape. The muscle growth guide covers GH-mediated body composition research.
PSPeptides: Quality, Supplies, and 24/7 Support
99%+ HPLC-verified purity with batch-specific COAs from independent laboratories. US manufacturing. Same-day processing seven days a week including Sundays. Free shipping on every domestic order. Free international shipping to 30+ countries over $150. Zero fees on all payment methods. Complete supplies — bacteriostatic water ($19.99), EasyTouch syringes, and alcohol prep pads — in one checkout. free reconstitution calculator with visual syringe diagrams. 24/7 support via live chat, email ([email protected]), phone/text (551) 284-2670. Discrete plain white mailer packaging with generic billing descriptors. 5-star rating from thousands of verified customers at pspeptides.com/shop.
Understanding tesamorelin dosage is essential for researchers navigating this rapidly evolving field in 2026.
Frequently Asked Questions
What is the standard tesamorelin dosage?
2mg subcutaneous daily — the FDA-approved dose validated in Phase III trials with 806 participants showing 15.4% visceral fat reduction vs placebo.
Is tesamorelin FDA-approved?
Yes — tesamorelin (Egrifta) was FDA-approved in 2010. The updated EGRIFTA WR formulation gained approval March 2025. It is the only FDA-approved GHRH peptide.
Does PSPeptides sell tesamorelin?
Yes. Research-grade tesamorelin from $59.99. 99%+ purity, batch-specific COAs, free shipping, same-day processing.
How does tesamorelin compare to Sermorelin?
Tesamorelin has FDA approval and Phase III validation (806 participants). Sermorelin’s approval was withdrawn. Both target GHRHR but tesamorelin has stronger clinical evidence. PSPeptides carries both.
All PSPeptides products are sold exclusively for research and laboratory use.